Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals reported standalone revenue of Rs. 6,651 crore for FY2026, up ~10.3% from Rs. 6,033 crore in the prior year. Profit After Tax surged to Rs. 503 crore from Rs. 115 crore in the prior year — a jump of ~337% year-on-year, boosted significantly by a Rs. 100.27 crore deferred tax asset recognised due to the Finance Act amendment. The company recorded exceptional items totalling Rs. 66.99 crore for the year, comprising a Rs. 48.64 crore labour code provision and a Rs. 18.35 crore write-down on Sikkim manufacturing assets classified as held for sale. EBITDA margin expanded from 15.74% to 16.82%. The Board recommended a dividend of Rs. 12 per share (600%), up from Rs. 11 (550%) in the prior year. Statutory auditors KKC & Associates LLP issued an unmodified opinion on both standalone and consolidated results.
The sharp PAT growth driven by deferred tax credit is a one-off benefit; underlying operational performance shows steady margin expansion. The Sikkim asset write-down signals ongoing stress at that facility. The increased dividend signals management confidence.